Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.

NCT ID: NCT06865274

Last Updated: 2025-03-07

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-20
• Study Completion Date: 2027-02-28

Brief Summary

The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in a a comparison group of patients affected with Multiple Sclerosis (MS).

The study will involve adult patients diagnosed with MS, NMOSD, or MOGAD, followed at various clinical centers in the Lazio region.

Patients from the participating clinical centers will be selected, and their medical records will be analyzed to collect clinical and neuroimaging data. The data will include demographic information such as age, sex and body mass index and clinical information such as age at disease onset, disease duration, antibody status (AQP4+/- and MOG+/-), disease-modifying therapies, as well as MRI data and the Expanded Disability Status Scale (EDSS) score.

Each patient included in the study will undergo a single blood draw of approximately 5 ml of peripheral venous blood during routine blood tests, which will be used for DNA extraction and polimorphysm analysis. Demographic and clinical differences between patients with NMOSD and MOGAD, with and without the polymorphism, will be assessed and compared with the group of patients with MS.

Detailed Description

FCG receptors (FCGR) are proteins expressed by various immune cells that bind to the Fc portion of immunoglobulin G (IgG). They play a key role in innate and adaptive immunity, regulating inflammatory responses and preventing autoimmunity. Genetic studies have shown that variations in FCGR genes can influence these functions, altering phagocytosis capacity and inflammatory response.

One particularly relevant polymorphism is SNP rs396991 in the FCGR3A gene, which encodes the receptor expressed on NK cells, monocytes, and macrophages. This SNP causes the substitution of the amino acid phenylalanine (F) with valine (V) at position 158, modifying the receptor's affinity for IgG. The 158V variant is associated with an enhanced inflammatory response, while 158F is linked to reduced immune complex clearance, contributing to the pathogenesis of autoimmune diseases such as lupus, rheumatoid arthritis, and sarcoidosis.

Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are two inflammatory disorders of the central nervous system, often severe and recurrent. NMOSD is characterized by autoantibodies against aquaporin-4 (AQP4), while MOGAD is associated with autoantibodies against MOG glycoprotein. There are currently no data on the frequency of the rs396991 polymorphism in the Italian population affected by these diseases.

The primary objective of this study is to assess the frequency of the FCGR3A-V158F genetic polymorphism in a cohort of Italian patients affected by NMOSD and MOGAD. A comparison group composed of patients diagnosed with Multiple Sclerosis (MS) will also be included.

The study will involve adult patients diagnosed with MS, NMOSD, or MOGAD, receiving care at various clinical centers in the Lazio region. Patients from the participating clinical centers will be selected, and their medical records, both paper-based and digital, will be reviewed to collect clinical and neuroimaging data. These data will be organized in an Excel database and will include information such as age, sex, ethnic background, body mass index, smoking status, presence of other autoimmune diseases, and non-neurological comorbidities. Additional recorded information will include diagnosis (NMOSD, MS, or MOGAD), age at disease onset, disease duration, antibody status (AQP4+/- and MOG+/-), previous disease-modifying therapies and their duration, as well as MRI data and Expanded Disability Status Scale (EDSS) scores.

For genetic analysis, each patient included in the study will undergo a blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) during routine blood tests. The sample will be used for DNA extraction, following the patient's signed informed consent. Genetic investigations will be conducted at the Genomic Medicine Section of the Department of Life Sciences and Public Health at Università Cattolica del Sacro Cuore in Rome. DNA samples will be stored anonymously for up to 10 years from the start of the project, with access restricted to authorized personnel. Patients or their families may request the destruction of their DNA at any time.

A total of 50 patients will be recruited, with a 12-month enrollment period and a total study duration of 24 months. The secondary objective is to identify potential differences in the clinical characteristics of NMOSD and MOGAD patients who express the polymorphism compared to those who do not.

Genetic analyses will be conducted at the Section of Genomic Medicine, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore (Rome). The extracted DNA will be stored anonymously with an alphanumeric code for a maximum of 10 years from the start date of the project at the same institution. Only a limited number of authorized personnel will have access to the samples and data, subject to approval from the principal investigator (Prof. Massimiliano Mirabella). If requested by the patient or their family, the DNA can be destroyed at any time.

DNA extraction will be performed using the Wizard Genomic DNA Isolation Kit (Promega) and quantified via spectrophotometer (Thermo Fisher) and agarose gel electrophoresis. The detection of the rs396991 polymorphism in the FCGR3A gene in patients with NMOSD, MS, and MOGAD will be carried out using Sanger sequencing, employing primers described by Mahaweni et al. (14).

The presence of Copy Number Variable Regions (CNRs) in the FCGR3A gene will be assessed through MLPA (MRC Holland) and will be reserved only for patients who test negative for the rs396991 polymorphism using the Sanger method.

Conditions

Neuromyelitis Optica Spectrum Disorders; MOGAD; Multiple Sclerosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patients diagnosied with neuromyelitis optica spectrum disorder and MOG antibodies associated diseas

Patients will undergo a peripheral venous blood draw of approximately 5 ml (collected in EDTA) during routine blood tests for DNA extraction and genetic analysis, limited to the reserach of FCG3A polymorphisms. The results obtained will be compared with a control-group composed by patients diagnosed with Multiple sclerosis.

Group Type: OTHER

Blood draw for the laboratory assessment

Intervention Type: PROCEDURE

Blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms

Patients diagnosied with Multiple Sclerosis

Patients will undergo a peripheral venous blood draw of approximately 5 ml (collected in EDTA) during routine blood tests for DNA extraction and genetic analysis, limited to the reserach of FCG3A polymorphisms. This is a comparison group.

Group Type: OTHER

Blood draw for the laboratory assessment

Intervention Type: PROCEDURE

Blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms

Interventions

Blood draw for the laboratory assessment

Blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers
• Patients aged ≥ 18 years
• Ability to understand and sign informed consent

Exclusion Criteria

• Individuals under 18 years of age
• Inability to provide informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role: lead

Responsible Party

Mirabella Massimiliano

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Roma, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Massimiliano Mirabella, Neurology Associate Professor

Role: CONTACT

massimiliano.mirabella@policlinicogemelli.it

0630155390

Facility Contacts

Massimiliano Mirabella

Role: primary

massimiliano.mirabella@policlinicogemelli.it

0630155390

References

Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, de Haas M, de Boer M, Roos D, Kuijpers TW. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat. 2009 May;30(5):E640-50. doi: 10.1002/humu.20997.

Reference Type: BACKGROUND

PMID: 19309690 (View on PubMed)

Asano K, Matsumoto T, Umeno J, Hirano A, Esaki M, Hosono N, Matsui T, Kiyohara Y, Nakamura Y, Kubo M, Kitazono T. Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis. Inflamm Bowel Dis. 2013 Sep;19(10):2061-8. doi: 10.1097/MIB.0b013e318298118e.

Reference Type: BACKGROUND

PMID: 23917248 (View on PubMed)

Nieto A, Caliz R, Pascual M, Mataran L, Garcia S, Martin J. Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum. 2000 Apr;43(4):735-9. doi: 10.1002/1529-0131(200004)43:43.0.CO;2-Q.

Reference Type: BACKGROUND

PMID: 10765917 (View on PubMed)

Edberg JC, Langefeld CD, Wu J, Moser KL, Kaufman KM, Kelly J, Bansal V, Brown WM, Salmon JE, Rich SS, Harley JB, Kimberly RP. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum. 2002 Aug;46(8):2132-40. doi: 10.1002/art.10438.

Reference Type: BACKGROUND

PMID: 12209518 (View on PubMed)

Morgan AW, Robinson JI, Barrett JH, Martin J, Walker A, Babbage SJ, Ollier WE, Gonzalez-Gay MA, Isaacs JD. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther. 2006;8(4):R109. doi: 10.1186/ar1996.

Reference Type: BACKGROUND

PMID: 16846526 (View on PubMed)

Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997 Sep 1;100(5):1059-70. doi: 10.1172/JCI119616.

Reference Type: BACKGROUND

PMID: 9276722 (View on PubMed)

Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014;122:231-66. doi: 10.1016/B978-0-444-52001-2.00010-8.

Reference Type: BACKGROUND

PMID: 24507521 (View on PubMed)

Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, Weinstock-Guttman B. Multiple sclerosis. Lancet. 2024 Jan 13;403(10422):183-202. doi: 10.1016/S0140-6736(23)01473-3. Epub 2023 Nov 7.

Reference Type: BACKGROUND

PMID: 37949093 (View on PubMed)

Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-282. doi: 10.1016/S1474-4422(22)00431-8. Epub 2023 Jan 24.

Reference Type: BACKGROUND

PMID: 36706773 (View on PubMed)

Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2022 Aug 18;387(7):631-639. doi: 10.1056/NEJMra1904655. No abstract available.

Reference Type: BACKGROUND

PMID: 36070711 (View on PubMed)

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2019 Feb;19(1):5-20. doi: 10.1136/practneurol-2018-001899. Epub 2018 Nov 29.

Reference Type: BACKGROUND

PMID: 30498056 (View on PubMed)

Manger K, Repp R, Jansen M, Geisselbrecht M, Wassmuth R, Westerdaal NA, Pfahlberg A, Manger B, Kalden JR, van de Winkel JG. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis. 2002 Sep;61(9):786-92. doi: 10.1136/ard.61.9.786.

Reference Type: BACKGROUND

PMID: 12176802 (View on PubMed)

Dijstelbloem HM, Scheepers RH, Oost WW, Stegeman CA, van der Pol WL, Sluiter WJ, Kallenberg CG, van de Winkel JG, Tervaert JW. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum. 1999 Sep;42(9):1823-7. doi: 10.1002/1529-0131(199909)42:93.0.CO;2-X.

Reference Type: BACKGROUND

PMID: 10513795 (View on PubMed)

Capiod T. Cell proliferation, calcium influx and calcium channels. Biochimie. 2011 Dec;93(12):2075-9. doi: 10.1016/j.biochi.2011.07.015. Epub 2011 Jul 23.

Reference Type: BACKGROUND

PMID: 21802482 (View on PubMed)

Iannuzzi MC, Iyengar SK, Gray-McGuire C, Elston RC, Baughman RP, Donohue JF, Hirst K, Judson MA, Kavuru MS, Maliarik MJ, Moller DR, Newman LS, Rabin DL, Rose CS, Rossman MD, Teirstein AS, Rybicki BA. Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun. 2005 Sep;6(6):509-18. doi: 10.1038/sj.gene.6364235.

Reference Type: BACKGROUND

PMID: 15951742 (View on PubMed)

Chen JY, Wang CM, Tsao KC, Chow YH, Wu JM, Li CL, Ho HH, Wu YJ, Luo SF. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms of systemic lupus erythematosus in Taiwan. Ann Rheum Dis. 2004 Jul;63(7):877-80. doi: 10.1136/ard.2003.005892.

Reference Type: BACKGROUND

PMID: 15194589 (View on PubMed)

Morgan AW, Griffiths B, Ponchel F, Montague BM, Ali M, Gardner PP, Gooi HC, Situnayake RD, Markham AF, Emery P, Isaacs JD. Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis Rheum. 2000 Oct;43(10):2328-34. doi: 10.1002/1529-0131(200010)43:103.0.CO;2-Z.

Reference Type: BACKGROUND

PMID: 11037893 (View on PubMed)

Typiak MJ, Rebala K, Dudziak M, Dubaniewicz A. Polymorphism of FCGR3A gene in sarcoidosis. Hum Immunol. 2014 Apr;75(4):283-8. doi: 10.1016/j.humimm.2014.02.011. Epub 2014 Feb 12.

Reference Type: BACKGROUND

PMID: 24530756 (View on PubMed)

McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagace C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lordal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; NIDDK IBD Genetics Consortium; Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, Seielstad M. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010 Apr;42(4):332-7. doi: 10.1038/ng.549. Epub 2010 Mar 14.

Reference Type: BACKGROUND

PMID: 20228799 (View on PubMed)

Yesmin K, Hargreaves C, Newby PR, Brand OJ, Heward JM, Franklyn JA, Gough SC, Simmonds MJ. Association of FcGRIIa with Graves' disease: a potential role for dysregulated autoantibody clearance in disease onset/progression. Clin Endocrinol (Oxf). 2010 Jul;73(1):119-25. doi: 10.1111/j.1365-2265.2010.03780.x. Epub 2010 Feb 10.

Reference Type: BACKGROUND

PMID: 20148910 (View on PubMed)

Khor CC, Davila S, Breunis WB, Lee YC, Shimizu C, Wright VJ, Yeung RS, Tan DE, Sim KS, Wang JJ, Wong TY, Pang J, Mitchell P, Cimaz R, Dahdah N, Cheung YF, Huang GY, Yang W, Park IS, Lee JK, Wu JY, Levin M, Burns JC, Burgner D, Kuijpers TW, Hibberd ML; Hong Kong-Shanghai Kawasaki Disease Genetics Consortium; Korean Kawasaki Disease Genetics Consortium; Taiwan Kawasaki Disease Genetics Consortium; International Kawasaki Disease Genetics Consortium; US Kawasaki Disease Genetics Consortium; Blue Mountains Eye Study. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011 Nov 13;43(12):1241-6. doi: 10.1038/ng.981.

Reference Type: BACKGROUND

PMID: 22081228 (View on PubMed)

Duan J, Lou J, Zhang Q, Ke J, Qi Y, Shen N, Zhu B, Zhong R, Wang Z, Liu L, Wu J, Wang W, Gong F, Miao X. A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease: a case-control study and meta-analysis. PLoS One. 2014 Aug 5;9(8):e103329. doi: 10.1371/journal.pone.0103329. eCollection 2014.

Reference Type: BACKGROUND

PMID: 25093412 (View on PubMed)

Clark MR, Stuart SG, Kimberly RP, Ory PA, Goldstein IM. A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol. 1991 Aug;21(8):1911-6. doi: 10.1002/eji.1830210820.

Reference Type: BACKGROUND

PMID: 1831131 (View on PubMed)

Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991 Aug 15;147(4):1338-43.

Reference Type: BACKGROUND

PMID: 1831223 (View on PubMed)

Willcocks LC, Carr EJ, Niederer HA, Rayner TF, Williams TN, Yang W, Scott JA, Urban BC, Peshu N, Vyse TJ, Lau YL, Lyons PA, Smith KG. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7881-5. doi: 10.1073/pnas.0915133107. Epub 2010 Apr 12.

Reference Type: BACKGROUND

PMID: 20385827 (View on PubMed)

Niederer HA, Willcocks LC, Rayner TF, Yang W, Lau YL, Williams TN, Scott JA, Urban BC, Peshu N, Dunstan SJ, Hien TT, Phu NH, Padyukov L, Gunnarsson I, Svenungsson E, Savage CO, Watts RA, Lyons PA, Clayton DG, Smith KG. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet. 2010 Aug 15;19(16):3282-94. doi: 10.1093/hmg/ddq216. Epub 2010 May 27.

Reference Type: BACKGROUND

PMID: 20508037 (View on PubMed)

Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, Lehner PJ, Ouwehand WH, Allen JM, Watkins NA, Smith KG. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med. 2005 Oct;11(10):1056-8. doi: 10.1038/nm1288. Epub 2005 Sep 18.

Reference Type: BACKGROUND

PMID: 16170323 (View on PubMed)

Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008 Jan;8(1):34-47. doi: 10.1038/nri2206.

Reference Type: BACKGROUND

PMID: 18064051 (View on PubMed)

Nimmerjahn F, Ravetch JV. FcgammaRs in health and disease. Curr Top Microbiol Immunol. 2011;350:105-25. doi: 10.1007/82_2010_86.

Reference Type: BACKGROUND

PMID: 20680807 (View on PubMed)

Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009 Apr 16;113(16):3716-25. doi: 10.1182/blood-2008-09-179754. Epub 2008 Nov 18.

Reference Type: BACKGROUND

PMID: 19018092 (View on PubMed)

Other Identifiers

7168

Identifier Type: -

Identifier Source: org_study_id